Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Agenus Inc (AGEN)

Agenus Inc (AGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Agenus to Host First 2026 Stakeholder Webcast Business Wire - Tue Jan 20, 5:24PM CST

Access to Acceleration: Agenus’ BOT+BAL Global Momentum Entering 2026 Webcast on Wednesday, January 28, 2026, at 4:00 p.m. ET

AGEN : 3.37 (+0.90%)
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness Business Wire - Thu Jan 15, 6:01AM CST

Agenus Inc . ( Nasdaq: AGEN ), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd....

AGEN : 3.37 (+0.90%)
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas Business Wire - Mon Jan 12, 6:30AM CST

Updated national AAC protocol supports hospital-based, fully-reimbursed compassionate access across three solid tumor settings

AGEN : 3.37 (+0.90%)
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC Business Wire - Tue Dec 23, 2025

Deep and durable responses observed in a heavily pretreated, historically immunotherapy-resistant population Findings reinforce the broad, pan-tumor activity...

AGEN : 3.37 (+0.90%)
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL Business Wire - Wed Nov 19, 2025

Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET

AGEN : 3.37 (+0.90%)
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC Business Wire - Tue Nov 18, 2025

Agenus Inc. (Nasdaq: AGEN) , a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as ...

AGEN : 3.37 (+0.90%)
Agenus: Q3 Earnings Snapshot AP - Mon Nov 10, 2025

Agenus: Q3 Earnings Snapshot

AGEN : 3.37 (+0.90%)
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances Business Wire - Mon Nov 10, 2025

France grants reimbursed access with patients having commenced treatment Two-year BOT/BAL survival presented at ESMO spanning more than five cancers in...

AGEN : 3.37 (+0.90%)
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report Business Wire - Wed Nov 5, 2025

Agenus Inc. (“Agenus”) (Nasdaq: AGEN ), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financial results before the market...

AGEN : 3.37 (+0.90%)
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025 Business Wire - Fri Oct 17, 2025

Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and with active liver metastases Signals of tumor agnostic...

AGEN : 3.37 (+0.90%)

Barchart Exclusives

Trump’s Greenland Threats Scaring You Off? Buy This Dividend Stock as a Hedge Barchart - Tue Jan 20, 6:30PM CST
Trump's threats to seize Greenland have led to a selloff in risk assets while precious metals have rallied amid the flight to safe-haven assets. Agnico-Eagle Mines is a good dividend stock to buy amid the geopolitical turmoil. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot